eyeforpharma

Dr. Bates’ Talkback: 6 tips for ensuring oncology marketing success

Andree Bates, (Jan 25, 2012)

Dr. Andree K. Bates outlines what oncology marketers need to do to ensure commercial success
Pharma marketing and sales: When to make an Rx to OTC switch

Angelo DePalma, (Jan 24, 2012)

Angelo DePalma explores prescription to over-the-counter (Rx to OTC) switches as a strategy for extending a product’s commercial life
Pharma forecasting: How to fine tune market research

Andrew Tolve, (Jan 19, 2012)

Todd Johnson of Kantar Health outlines how market research can be honed into reliable data to improve forecasts
Pharma and KOLs: How to create transparent, collaborative relationships

phil7taylor, (Jan 17, 2012)

Phil Taylor explores how pharma’s relationship to key opinion leaders is changing - for the better

Jeanne Barnett, (Jan 26, 2012)

How to protect the data on your iPad2

EileenOBrien, (Jan 25, 2012)

A review of the most pharma-relevant changes to YouTube

Malcolm Allison, (Jan 25, 2012)

How I learned to love the iPad a little bit less

Patients need to know the risks of non-adherence as much as the risks of medication

Malcolm Allison, (Jan 20, 2012)

How I learned to love the iPad

Emerging pharma markets: How to profit in Latin America

Ursula Sautter, (Jan 6, 2012)

Eyeforpharma's Ursula Sautter talks to Rafael Quintanilla Chong, head of primary care at Bayer Healthcare Mexico, about the promise of the Latin American market
The Mobile Health Competition

Andrew Tolve, (Nov 24, 2011)

Teenagers with cancer often report feelings of isolation, bitterness, confusion, pain, and fear as they struggle through a life-threatening disease before their lives have taken full shape.
A 6-step guide to KOL engagement

Andrew Tolve, (Nov 23, 2011)

Six novel ways pharma can identify and engage with key opinion leaders (KOLs)

More Sales

Understanding pharma’s drug development costs

Angelo DePalma, (Jan 3, 2012)

Angelo DePalma explores what it costs to bring a new drug to market—and why it matters
The Mobile Health Competition

Andrew Tolve, (Nov 24, 2011)

Teenagers with cancer often report feelings of isolation, bitterness, confusion, pain, and fear as they struggle through a life-threatening disease before their lives have taken full shape.
Dr. Bates’ Talkback: 10 questions for an ‘MBA clone’ diagnosis

Andree Bates, (Nov 18, 2011)

Are you an ‘MBA clone’? Dr. Andrée K Bates explores how de-cloning yourself does wonders for your ability to thrive in competitive markets

More Marketing

Q&A: Making adherence effective, economic and scalable

Editor, (Jan 11, 2012)

Professors John Weinman of Kings College London and Keith Petrie of the University of Auckland on the future of medication adherence
Dr. Bates’ Talkback: 4 ways to improve patient adherence, part I

Andree Bates, (Dec 1, 2011)

In the first of a two-part series, Dr. Andree K. Bates explores how changes to the drug and technology can improve patient adherence
The Mobile Health Competition

Andrew Tolve, (Nov 24, 2011)

Teenagers with cancer often report feelings of isolation, bitterness, confusion, pain, and fear as they struggle through a life-threatening disease before their lives have taken full shape.

More Patients

Pharma forecasting: The changing role of patients

Andrew Tolve, (Jan 17, 2012)

Milos Graonic, senior vice president, global leader of Nielsen BASES Pharmaceutical Practice, on how to mine patient data for forecasting insights
Forecasting 2.0: How to make forecasting a strategic imperative

Andrew Tolve, (Nov 6, 2011)

Prasad Saraph, business partner at Bayer HealthCare, explains why forecasting must reflect an organization’s collective intelligence
Forecasting the future of biologics

Peter Mansell, (Sep 15, 2011)

Peter Mansell reports on how to balance complexity and predictability when forecasting for biologics

More Forecasting

Dr. Bates’ Talkback: How to profitably compete in the oncology market

Andree Bates, (Dec 13, 2011)

Dr. Andree K. Bates outlines key strategies for addressing the sales, marketing and market access challenges of the oncology market
Market access: How network intelligence increases value

Peter Wagner, (Dec 5, 2011)

Paolo Morgese of Merck Serono and Peter Wagner and Maximilian Schwarz of Mederi present 5 tips for matching stakeholders’ value expectations with demonstration of value
Market access: How to engage emerging stakeholders

Leela Barham, (Nov 6, 2011)

Leela Barham reports on how the pharma industry can make the most of working with emerging stakeholders

More Market Access